NEW
Flowflex® COVID-19
Antigen Home Test
A Simple Way to Test for COVID-19
ACON Laboratories, Inc. is the only legal manufacturer of the FDA EUA Flowflex COVID-19 Antigen Home Test.
Get Back to Sharing Special Moments
with Family and Friends
Find peace of mind with Flowflex!
- Easy-to-use nasal swab test
- Can be used to test children as young as 2 years old
- For use with and without COVID-19 symptoms
- Results in 15 minutes
- No need to send off to a lab to obtain results
- Compact packaging for “On-The-Go” testing
As of September 2, 2022, the expiration date of the Flowflex COVID-19 Antigen Home Test is extended by 7 months. Please click here to check the new expiration date using the lot number printed on the test kit box.
Test Procedure Overview
This test procedure overview does not replace the package insert. Before you begin the test, it is important to read and follow the detailed instructions in the package insert.
Videos
Adult Testing
Child Testing
Resources
Consumer Package Insert (English)
Consumer Package Insert (Spanish)
Fact Sheet for Healthcare Professionals
Healthcare Provider Package Insert
Quick Reference Instructions
Frequently Asked Questions
Where Can I Buy It?
For employee testing solutions, click here.
Looking for a Distributor?
Need Support?
News
PUBLIC NOTICE OF COUNTERFEIT FLOWFLEX™ COVID-19 TEST KITS
ACON Laboratories, Inc., has become aware that counterfeit versions of its FDA-authorized Flowflex® COVID-19 Antigen Home Tests in the 1 Test/ kit box configuration marked as Lot# COV2010030 and COV2030016 are being illegally distributed in the United States through...
Flowflex COVID-19 Antigen Home Test New Shelf-life Extension
Since the launch of its Flowflex COVID-19 Antigen Home Test, ACON Laboratories, Inc. has continued testing for product stability to extend the shelf-life. These results have been shared with the FDA. We are pleased to announce that the request to extend the Flowflex...
STATEMENT ON THE OMICRON BA.2.12.1, BA.4, and BA.5 VARIANTS
ACON Laboratories, Inc. has been continuously monitoring the emergence of SARS-CoV-2 variants. The Omicron variant of concern remains the dominant variant circulating globally, accounting for nearly all sequences submitted to GISAID. Among the Omicron variant,...
- In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
- This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
For more information on EUAs please visit: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19